Digital Image Analysis Of Her2 Immunostained Gastric And Gastroesophageal Junction Adenocarcinomas

Digital Image Analysis Of Her2 Immunostained Gastric And Gastroesophageal Junction Adenocarcinomas

Introduction/ Background Manual assessment of HER2 protein expression in gastric and gastroesophageal junction (GGEJ) adenocarcinomas is prone to inter-observer variability and hampered by tumor heterogeneity and different scoring criteria. Cases are frequently referred to FISH. Aims This study aime...

Full description

Bibliographic Details
Main Authors:	S.L. Nielsen, S. Nielsen, Mogens Vyberg
Format:	Article
Language:	English
Published:	DiagnomX 2016-06-01
Series:	Diagnostic Pathology
Online Access:	http://www.diagnosticpathology.eu/content/index.php/dpath/article/view/120

Similar Items

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
by: Julie Sigrand, et al.
Published: (2016-03-01)

Characteristics and Survival Rate of Patients with Gastric and Gastroesophageal Junction Adenocarcinoma in Yazd, Iran
by: Ali Akhavan, et al.
Published: (2013-07-01)

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas
by: Indu Rajagopal, et al.
Published: (2015-03-01)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
by: Daniel Walden, et al.
Published: (2021-09-01)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
by: Dan Zhao, et al.
Published: (2019-05-01)

HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.
by: Dan Huang, et al.
Published: (2013-01-01)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
by: Gagandeep Brar, et al.
Published: (2019-08-01)

Gastroesophageal junction adenocarcinoma. A case report
by: Marcos Félix Osorio Pagola, et al.
Published: (2010-12-01)

Gastroesophageal junction adenocarcinoma. A case report
by: Marcos Félix Osorio Pagola, et al.
Published: (2010-12-01)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
by: Yuan Tian, et al.
Published: (2021-01-01)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
by: Fattoruso Silvia, et al.
Published: (2009-03-01)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States
by: Bradford J. Kim, et al.
Published: (2020-10-01)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
by: Maria Angeles Gil-Delgado, et al.
Published: (2018-08-01)

Synchronous Gastrointestinal Stromal Tumor and Adenocarcinoma at the Gastroesophageal Junction
by: Hui-Hua Hsiao, et al.
Published: (2009-06-01)

Inguinal mass: An unusual presentation of gastroesophageal junction adenocarcinoma
by: Gourav Kaushal, et al.
Published: (2017-01-01)

Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas
by: Xianchun Gao, et al.
Published: (2021-02-01)

Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.
by: Sabina Berezowska, et al.
Published: (2013-01-01)

Meningeal Carcinomatosis: A Metastasis from Gastroesophageal Junction Adenocarcinoma
by: Tanya Dam, et al.
Published: (2013-01-01)

Incidence of microscopically positive proximal margins in adenocarcinoma of the gastroesophageal junction.
by: Fei Gao, et al.
Published: (2014-01-01)

Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma.
by: Shu-Qin Dai, et al.
Published: (2013-01-01)

Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors
by: Charles Caldwell, et al.
Published: (2021-05-01)

The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples
by: Federica Grillo, et al.
Published: (2013-02-01)

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
by: Cen, L., et al.
Published: (2022)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
by: Yulia Kundel, et al.
Published: (2020-10-01)

The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma
by: Kate Dinneen, et al.
Published: (2021-02-01)

Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction.
by: Morteza Bashash, et al.
Published: (2013-01-01)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)

Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair
by: Dewalt RI, et al.
Published: (2014-02-01)

HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
by: Brett L Ecker, et al.
Published: (2016-01-01)

Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study
by: Sebastian Ochenduszko, et al.
Published: (2017-04-01)

PTEN loss is associated with a poor response to trastuzumab in HER2- overexpressing gastroesophageal adenocarcinoma
by: Deguchi, Yasunori
Published: (2017)

Genomic and transcriptomic alterations associated with drug vulnerabilities and prognosis in adenocarcinoma at the gastroesophageal junction
by: Yuan Lin, et al.
Published: (2020-11-01)

HER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors
by: Maha Arafah, et al.
Published: (2010-10-01)

Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
by: Laura W Goff, et al.
Published: (2014-01-01)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
by: Yokoyama, Daiju
Published: (2021)

PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma
by: Daiju Yokoyama, et al.
Published: (2021-04-01)

The Efficacy of Ramucirumab in the Treatment of Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis of RCTs
by: Hongqiong Yang, et al.
Published: (2021-01-01)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
by: K Govind Babu, et al.
Published: (2019-01-01)